Home › Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
 

Keywords :   


Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

2014-10-22 15:11:12| Biotech - Topix.net

Ipsen and Lexicon Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.

Tags: enter agreement licensing lexicon

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11
23.11 NEXT
23.11
23.11(Rawlings)
23.11 DVD2
23.11
23.11 US Orig LP The Soul Searchers Salt Of ~
23.11Switch SR SL LED 2
More »